An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
We have developed recombinant vesicular stomatitis virus (VSV) vectors expressing the Yersinia pestis lcrV gene. These vectors, given intranasally to mice, induced high antibody titers to the LcrV protein and protected against intranasal (pulmonary) challenge with Y. pestis. High-level protection was dependent on using an optimized VSV vector that expressed high levels of the LcrV protein from an lcrV gene placed in the first position in the VSV genome, followed by a single boost. This VSV-based vaccine vector system has potential as a plague vaccine protecting against virulent strains lacking the F1 protein.
Palin
Amy
A
Department of Pathology, Yale University School of Medicine, 310 Cedar Street (LH 315), New Haven, CT 06510, USA.
Chattopadhyay
Anasuya
A
Park
Steven
S
Delmas
Guillaume
G
Suresh
Rema
R
Senina
Svetlana
S
Perlin
David S
DS
Rose
John K
JK
D000281:Administration, Intranasal; D000818:Animals; D005260:Female; D007117:Immunization, Secondary; D051379:Mice; D008807:Mice, Inbred BALB C; D010930:Plague / Q000517:prevention & control*; D010931:Plague Vaccine / Q000008:administration & dosage / Q000276:immunology*; D013997:Time Factors; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics*; D015010:Yersinia pestis / Q000276:immunology*
D010931:Plague Vaccine